CONTENTS VOL. 23, 2005

Volume 23, No 1

Preclinical Studies

Investigation of HMN-176 anticancer activity in human tumor specimens *in vitro* and the effects of HMN-176 on differential gene expression – L. Medina-Gundrum, C. Cerna, L. Gomez, E. Izbicka 3–9

Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions – E. P. Lansky, W. Jiang, H. Mo, L. Bravo, P. Froom, W. Yu, N. M. Harris, I. Neeman, M. J. Campbell 11–20

Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123 – M.-S. Si, B. A. Reitz, D. C. Borie 21–29

Phase I and Pharmacokinetic Studies

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor – J. L. Marshall, H. Kindler, J. Deeken, P. Bhargava, N. J. Vogelzang, N. Rizvi, T. Luhtala, S. Boylan, M. Dordal, P. Robertson, M. J. Hawkins, M. J. Ratain 31–37

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects – A. K. Bence, E. B. Anderson, M. A. Halepota, M. A. Doukas, P. A. DeSimone, G. A. Davis, D. A. Smith, K. M. Koch, A. G. Stead, S. Mangum, C. J. Bowen, N. L. Spector, S. Hsieh, V. R. Adams 39–49

Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98) – G. A. Bjarnason, D. Charpentier, R. Wong, R. Goel, L. Douglas, W. Walsh, S. Matthews, S. Dent, L. Seymour 51–56

Phase I and Pharmacokinetic Studies (cont'd)

Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors – B. F. El-Rayes, D. Ibrahim, A. F. Shields, P. M. LoRusso, M. M. Zalupski, P. A. Philip 57–62

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin – R. Goel, E. Chouinard, D. J. Stewart, S. Huan, H. Hirte, S. Stafford, B. Waterfield, J. Roach, C. Lathia, V. Agarwal, R. Humphrey, W. Walsh, S. Matthews, L. Seymour 63–71

Phase II Studies

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status – G.-C. Chang, K.-C. Chen, T.-Y. Yang, M.-C. Yin, C.-P. Lin, B. I.-T. Kuo, J.-Y. Hsu 73–77

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC) – T. Latif, L. Wood, C. Connell, D. C. Smith, D. Vaughn, D. Lebwohl, D. Peereboom 79–84

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer – F. Caponigro, P. Willemse, R. Sorio, A. Floquet, S. van Belle, J. Demol, R. Tambaro, A. Comandini, A. Capriati, S. Adank, J. Wanders 85–89

Instructions for authors 91–94

Volume 23, No 2

Preclinical Studies

Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines – J. Sonnemann, J. Gänge, K. S. Kumar, C. Müller, P. Bader, J. F. Beck 99–109

Resveratrol regulates cellular PKC α and δ to inhibit growth and induce apoptosis in gastric cancer cells – M. J. Atten, E. Godoy-Romero, B. M. Attar, T. Milson, M. Zopel, O. Holian 111–119

Pomegranate (*Punica granatum*) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel™ – E. P. Lansky, G. Harrison, P. Froom, W. G. Jiang 121–122

Phase I and Related Studies

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer – J. Murren, M. Modiano, S. Kummar, C. Clairmont, M. Egorin, E. Chu, M. Sznol 123–135

Transient respiratory failure possibly associated to imatinib – C. Lengerke, T. Brümmendorf, U. Herrlinger, M. Horger, L. Kanz, J. T. Hartmann 137–138

Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study – P. Schmid, M. Schweigert, T. Beinert, B. Flath, O. Sezer, K. Possinger 139–146

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group – G. Goss, H. Hirte, W. H. Miller Jr, I. A. J. Lorimer, D. Stewart, G. Batist, D. A. E. Parolin, P. Hanna, S. Stafford, J. Friedmann, W. Walsh, S. Mathews, L. Douglas, L. K. Seymour 147–155

Impact of taurolidin and octreotide on liver metastasis and lipid peroxidation after laparoscopy in chemical induced ductal pancreatic cancer – M. Kilian, J. I. Gregor, I. Heukamp, C. Braumann, H. Guski, I. Schimke, M. K. Walz, C. A. Jacobi, F. A. Wenger 157–164

Phase II Studies

A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer – M. J. MacKenzie, H. W. Hirte, G. Goss, J. Maroun, R. Goel, P. P. Major, W. H. Miller Jr., L. Panasci, I. A. J. Lorimer, G. Batist, S. Matthews, L. Douglas, L. Seymour 165–170

Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: A phase II trial – T.-C. Chao, Z. Chu, L.-M. Tseng, T.-J. Chiou, R.-K. Hsieh, W.-S. Wang, C.-C. Yen, M.-H. Yang, L.-T. Hsiao, J.-H. Liu, P.-M. Chen 171–177

Phase II trial of fenretinide in advanced renal carcinoma – U. Vaishampayan, L. K. Heilbrun, R. E. Parchment, V. Jain, J. Zwiebel, R. R. Boinpally, P. LoRusso, M. Hussain 179–185

Instructions for authors 187–189

Volume 23, No 3

Preclinical Studies

A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug – C. Fimognari, L. Sangiorgi, S. Capponcelli, M. Nüsse, S. Fontanesi, F. Berti, S. Soddu, G. Cantelli-Forti, P. Hrelia 195–203

Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines – F. Mayer, S. Mueller, E. Malenke, M. Kuczyk, J. T. Hartmann, C. Bokemeyer 205–211

Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumors – Jian Liang, Richard E. Moore, Eric D. Moher, John E. Munroe, Rima S. Al-awar, David A. Hay, David L. Varie, Tony Y. Zhang, James A. Aikins, Michael J. Martinelli, Chuan Shih, James E. Ray, Lowell L. Gibson, Vasu Vasudevan, Lisa Polin, Kathryn White, Juiwanna Kushner, Chiab Simpson, Susan Pugh, Thomas H. Corbett 213–224

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam – C. van Kesteren, A. S. Zandvliet, M. O. Karlsson, R. A. A. Mathôt, C. J. A. Punt, J.-P. Armand, E. Raymond, A. D. R. Huitema, C. Dittrich, H. Dumez, H. H. Roché, J.-P. Droz, M. Ravic, S. M. Yule, J. Wanders, J. H. Beijnen, P. Fumoleau, J. H. M. Schellens 225–234

Phase I and Related Studies

Phase I trial of menadiol diphosphate (vitamin K_3) in advanced malignancy – D. Lim, R. J. Morgan, Jr., S. Akman, K. Margolin, B. I. Carr, L. Leong, O. Odujinrin, J. H. Doroshow 235–239

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer – H. Wakelee, G. A. Fisher 241–242

Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer – M. Méndez, P. G. Alfonso, E. Pujol, E. González, C. Castañon, P. Cerezuela, Y. López-Mateos, J. J. Cruz 243–251

Phase II Studies

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma – M. J. Millward, A. Joshua, R. Kefford, S. Aamdal, D. Thomson, P. Hersey, G. Toner, K. Lynch 253–256

Phase II trial of dolastatin-10 in patients with advanced breast cancer – E. A. Perez, D. W. Hillman, P. A. Fishkin, J. E. Krook, W. W. Tan, P. A. Kuriakose, S. R. Alberts, S. R. Dakhil 257–261

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer – J. Vansteenkiste, J.-L. Canon, H. Riska, R. Pirker, P. Peterson, W. John, P. Mali, M. Lahn 263–269

Instructions for authors 271–273

Volume 23, No 4

Preclinical Studies

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid – Stefan R. Vink, Jan H.M. Schellens, Wim J. van Blitterswijk, Marcel Verheij 279–286

Enhanced *P53* and *BAX* gene expression and apoptosis in A549 cells by *cis*-Pt(II) complex of 3-aminoflavone in comparison with *cis*-DDP – Beata Kosmider, Izabela Wojcik, Regina Osiecka, Jacek Bartkowiak, Elzbieta Zyner, Justyn Ochocki, Pawel Liberski 287–297

A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines – Kongming Wu, Mark D'Amico, Chenguang Wang, Chris Albanese, Richard G. Pestell, Sridhar Mani 299–309

Phase I Studies

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer – Kim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon 311–315

Human metabolism of [^{14}C]indisulam following i.v. infusion in cancer patients – Jan-Hendrik Beumer, Michel J.X. Hillebrand, Dick Pluim, Hilde Rosing, Karen Foley, S. Murray Yule, Jan H.M. Schellens, Jos H. Beijnen 317–330

Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer – Takahiko Sugiura, Yutaka Ariyoshi, Shunichi Negoro, Shinichiro Nakamura, Harumichi Ikegami, Minoru Takada, Takashi Yana, Masahiro Fukuoka 331–337

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors – Moritz N. Wente, Jörg Kleeff, Markus W. Büchler, Jantien Wanders, Peter Cheverton, Stephen Langman, Helmut Friess 339–347

Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study – Peter Schmid, Bernd Flath, Konstantin Akrivakis, Volker Heilmann, Hans-Günther Mergenthaler, Orhan Sezer, Rolf Kreienberg, Kurt Possinger 349–356

Phase II Studies

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme – Susan M. Chang, Patrick Wen, Timothy Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Lisa De Angelis, Jeffrey Raizer, Kenneth Hess, Ken Aldape, Kathleen R. Lamborn, John Kuhn, Janet Dancey, Michael D. Prados 357–361

BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR) – R.-D. Hofheinz, C. Porta, G. Hartung, A. Santoro, A.-R. Hanauske, K. Kutz, A. Stern, P. Barbieri, E. Verdi, R. Hehlmann, A. Hochhaus 363–368

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study – Nicolas Tsavaris, Christos Kosmas, Helias Skopelitis, Panagiotis Gouveris, Petros Kopterides, Dioynissis Loukeris, Frantzeska Sigala, Alexandra Zorbala-Sypsa, Evangelos Felekouras, Efstathios Papalambros 369–375

Erratum 377

Erratum 379

Instructions for authors 381–383

Volume 23, No 5

Preclinical Studies

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer – Christina H. Yeon, Mark D. Pegram 391–409

Novel therapy in multiple myeloma – Agustin Avilés, Natividad Neri, M. Jesús Nambo, Sergio Cleto, Claudia Castañeda, Martha González, Alejandra Talavera, Judith Huerta-Guzmán 411–415

Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists – Doris M. Benbrook, Scott A. Kamelle, Suresh B. Guruswamy, Stan A. Lightfoot, Teresa L. Rutledge, Natalie S. Gould, Bethany N. Hannafon, S. Terence Dunn, K. Darrell Berlin 417–428
Trabectedin (Yondelis™, formerly ET-743), a mass balance study in patients with advanced cancer – J.H. Beumer, J.M. Rademaker-Lakhai, H. Rosing, L. Lopez-Lazaro, J.H. Beijnen, J.H.M. Schellens 429–436

Phase I Studies

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin – H. Hirte, D. Stewart, R. Goel, E. Chouinard, S. Huan, S. Stafford, B. Waterfield, S. Matthews, C. Lathia, B. Schwartz, V. Agarwal, R. Humphrey, L. Seymour 437–443
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130 – Karen A. Gelmon, Karl Belanger, Denis Soulieres, Carolyn Britten, Stephen Chia, Danielle Charpentier, Kim Chi, Jean Powers, Wendy Walsh, Lesley Seymour 445–453
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies – Eric X. Chen, Gerald Batist, Lillian L. Siu, Naeema Bangash, Martha Maclean, Lynn McIntosh, Wilson H. Miller Jr, Amit M. Oza, Chetan Lathia, Oana Petrenciuc, Lesley Seymour 455–465
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer – Ranjana Advani, Bert L. Lum, George A. Fisher, Joanne Halsey, Richard S. Geary, Jon T. Holmlund, T. Jesse Kwoh, F. Andrew Dorr, Branimir I. Sikic 467–477

Phase II Studies

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer – Jaffer A. Ajani, Chris Takimoto, Carlos R. Becerra, Alejandro Silva, Luis Baez, Allen Cohn, Pierre Major, Makio Kamida, Kevie Feit, Robert De Jager 479–484
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A SOUTHWEST oncology group (SWOG 9924) study – John S. Macdonald, Sheryl McCoy, Robert P. Whitehead, Syma Iqbal, James L. Wade III, Jeffrey K. Giguere, James L. Abbruzzese 485–487
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers – Hedy L. Kindler, Peter K. Tothy, Robert Wolff, Richard A. McCormack, James L. Abbruzzese, Sridhar Mani, Kurombi T. Wade-Oliver, Everett E. Vokes 489–493
Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial – Evanthia Galanis, Jan C. Buckner, Matthew J. Maurer, Joel M. Reid, Mary J. Kuffel, Matthew M. Ames, Bernd W. Scheithauer, Julie E. Hammack, George Pipoly, Steven A. Kuross 495–503

Instructions for authors 505–507

Volume 23, No 6

Special Issue: Recent Advances in Pharmacogenetic Approaches to Cancer Chemotherapy
Guest Editors: Alex Sparreboom and William D. Figg

Special Section

Introduction – Alex Sparreboom, William D. Figg 511
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes – Ron H.N. van Schaik 513–522
The thiopurines: An update – Sally Coulthard, Linda Hogarth 523–532
Thymidylate synthase pharmacogenetics – Sharon Marsh 533–537
Pharmacogenetics of irinotecan: A promoter polymorphism of *UGT1A1* gene and severe adverse reactions to irinotecan – Maki Ando, Yoshinori Hasegawa, Yuichi Ando 539–545

Preclinical Studies

Growth inhibition and apoptosis-induced effect on human cancer cells of toosendanin, a triterpenoid derivative from Chinese traditional medicine – Bin Zhang, Zhong-Feng Wang, Mian-Zhi Tang, Yu-Liang Shi 547–553

Phase I Studies

A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors – G.A. Otterson, J. Lavelle, M.A. Villalona-Calero, M. Shah, X. Wei, K.K Chan, B. Fischer, M. Grever 555–562

Phase II Studies

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer – Afshin Dowlati, Robert Chapman, Shanmuga Subbiah, Pingfu Fu, Anne Ness, Tania Cortas, Lauren Patrick, Sherrie Reynolds, Natalie Xu, Nathan Levitan, Percy Ivy, Scot C. Remick 563–567

Phase II study of perifosine in previously untreated patients with metastatic melanoma – D. Scott Ernst, Elizabeth Eisenhauer, Nancy Wainman, Mary Davis, Reinhard Lohmann, Tara Baetz, Karl Belanger, Michael Smylie 569–575

Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma – Philip E. Shaheen, Walter Stadler, Paul Elson, Jennifer Knox, Eric Winquist, Ronald M. Bukowski 577–581

A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer – Basil F. El-Rayes, Mark M. Zalupski, Anthony F. Shields, Ann Marie Ferris, Ulka Vaishampayan, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Volkan Adsay, Philip A. Philip 583–590

Phase II trial of SarCNU in malignant glioma: Unexpected pulmonary toxicity with a novel nitrosourea *A phase II trial of the national cancer institute of canada clinical trials group* – Marc Webster, Gregory Cairncross, Stan Gertler, James Perry, Nancy Wainman, Elizabeth Eisenhauer 591–596

Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination – Emilio Esteban-Gonzalez, Yolanda Fernández, Noemí Villanueva, Joaquin Fra, Isabel Muñiz, Isabel Palacio, Jose M. Vieitez, Esther Uña, Beatriz Mareque, Angel J. Lacave 597–601

Erratum 603

Volume Table of Contents for 2005 605–609

Instructions for authors 611–613